Antibióticos do Brasil expands Sao Paolo site by 25%

By Ben Hargreaves

- Last updated on GMT

(Image; Getty/Filipefrazao)
(Image; Getty/Filipefrazao)

Related tags Antibióticos do Brasil Brazil

The Brazil-headquartered antibiotics company announces that it has invested in two new buildings, a few years after running into regulatory trouble due to non-compliance with cGMP.

Antibióticos do Brasil (ABL) invested R$180m ($46m) in the expansion of its site in Cosmópolis, Sao Paolo, which was made to expand production capacity and to minimise the risk of contamination.

Two new buildings were added as part of the extension, which increased the built area by 36,000ft2 ​and the overall size of the facility by 25%.

Investe Sao Paulo, which provided environmental and infrastructure advice for the project, said the updated plant would create approximately 150 direct and indirect jobs in the region.

“The whole range of equipment and concepts are unique in the production of sterile antibiotics because they reduce human contact with the product, ensuring greater manufacturing safety,”​ says Sidnei Bianchi Júnior, plant manager for ABL.

The updates to its sterile antibiotics production arrive two years after Italy outright banned​ the active pharmaceutical ingredients (APIs) produced at the facility.

The decision was made after the Italian Medicines Agency (AIFA) sent a team of inspectors to the facility, which raised concerns about good manufacturing practice (GMP) awareness and the quality control conducted at the site.

The US Food and Drug Administration came to a similar conclusion when it inspected ABL’s facility the year prior​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more